-
Mashup Score: 13SABCS 2024 Archives - VJOncology - 2 day(s) ago
VJOncology are excited to attend the upcoming 47th San Antonio Breast Cancer Symposium (SABCS) 2024, bringing you the highly-anticipated trial data and insightful perspectives from leading experts in breast cancer! This international scientific symposium allows for important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer. Stay tuned for our coverage of the meeting, and catch up on the 2023 meeting below! VJOncology are
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the rationale and design of the Phase II ELCIN trial (NCT05596409) of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Based on the findings of the EMERALD trial (NCT03778931), which demonstrated significant progression-free survival benefits for elacestrant, the ELCIN trial further explores its efficacy and safety. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@VKaklamani from @UTHealthSA discusses the Phase II ELCIN trial on elacestrant for ER+/HER2- metastatic breast cancer, building on promising EMERALD trial findings: ➡️https://t.co/sIssdnpE52⬅️ @SABCSSanAntonio #SABCS24 #BreastCancer #BCSM
-
-
Mashup Score: 17
Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the rationale and design of the Phase II ELCIN trial (NCT05596409) of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Based on the findings of the EMERALD trial (NCT03778931), which demonstrated significant progression-free survival benefits for elacestrant, the ELCIN trial further explores its efficacy and safety. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
The Phase II ELCIN trial (NCT05596409) Report with Virginia Kaklamani (VJ Onc) https://t.co/NSV2FkCC71 evaluates the efficacy and safety of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Building on the results of the EMERALD trial (NCT03778931),… https://t.co/14Kj3tBMOh https://t.co/iQDOKY7kPc
-
-
Mashup Score: 17
Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the rationale and design of the Phase II ELCIN trial (NCT05596409) of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Based on the findings of the EMERALD trial (NCT03778931), which demonstrated significant progression-free survival benefits for elacestrant, the ELCIN trial further explores its efficacy and safety. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
The Phase II ELCIN trial (NCT05596409) Report with Virginia Kaklamani (VJ Onc) https://t.co/NSV2FkCC71 evaluates the efficacy and safety of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Building on the results of the EMERALD trial (NCT03778931),… https://t.co/14Kj3tBMOh https://t.co/iQDOKY7kPc
-
-
Mashup Score: 16
Icro Meattini, MD, University of Florence, Florence, Italy, discusses the interim findings of the Phase III EUROPA trial (NCT04134598), which compared radiotherapy and endocrine therapy in older adults with low-risk early breast cancer. At 24 months, radiotherapy resulted in significantly better health-related quality of life, with fewer declines in functional and symptom scales compared to endocrine therapy. No ipsilateral breast tumor recurrence, locoregional recurrence, nor distant metastases were observed in either group. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@Icro_Meattini of @UNI_FIRENZE discusses interim #EUROPA trial data: in older adults with low-risk early breast cancer, radiotherapy showed better QoL than endocrine therapy, with no recurrences: ➡️https://t.co/UGqJuAfInR⬅️ @SABCSSanAntonio #BreastCancer #SABCS24 #BCSM
-
-
Mashup Score: 20Role of GLP-1 agonists in breast cancer survivorship setting - 7 day(s) ago
Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential use of GLP-1 or GLP agonist and incretin mimetics during or after cancer therapy, particularly in breast cancer survivors, who are at risk for metabolic disorders such as diabetes and cardiovascular disease. Dr Iyengar notes that while weight loss drugs may be beneficial in the survivorship setting, their use during or immediately after cancer therapy is not currently recommended due to lack of safety data and potential toxicity. Dr Iyengar suggests that further research is needed to fully understand the effects of these medications on cancer treatment outcomes. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@Neil_Iyengar of @MSKCancerCenter discusses GLP-1 agonists in breast cancer survivorship, noting benefits for metabolic health but highlighting a lack of safety data during/after therapy: ➡️https://t.co/hSs9R08BQt⬅️ @SABCSSanAntonio #SABCS24 #BreastCancer #BCSM
-
-
Mashup Score: 10
Hans-Christian Kolberg, MD, Marienhospital Bottrop, Bottrop, Germany, comments on the results of the NeoMono trial, a Phase II neoadjuvant randomized clinical trial in triple-negative breast cancer patients, highlighting the importance of PD-L1 as a biomarker for immune checkpoint inhibitor therapy. Dr Kolberg notes that despite the trial’s unique design and high PCR rates, particularly in the PD-L1 positive population, no treatment interaction was observed, but PD-L1 remains a strong signal as an important biomarker. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥 Hans-Christian Kolberg, MD, discusses the NeoMono trial in #TNBC at #SABCS24: 🌟High PCR rates in PD-L1+ patients 🌟PD-L1 = key biomarker for immune checkpoint therapy ➡️https://t.co/bxiMcvqhck⬅️ @SABCSSanAntonio #BreastCancer #BCSM #ImmunoOnc #CTSM #TrialUpdates
-
-
Mashup Score: 3
Melissa Calopiz, University of Michigan, Ann Arbor, MI, explores the use of SimADC, a computational model for designing and evaluating antibody-drug conjugates (ADCs). By simulating immune cell interactions and payload release mechanisms, this approach aims to enhance ADC design, reduce toxicity, and improve therapeutic outcomes, especially in low-expression systems like those treated with trastuzumab deruxtecan. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥Melissa Calopiz of @UMich discusses SimADC, a model enhancing ADC design by simulating immune interactions & payload release, optimizing outcomes in low-expression systems like T-DXd: ➡️https://t.co/MLonkCQwdo⬅️ @SABCSSanAntonio #SABCS24 #BreastCancer #BCSM #ImmunoOnc
-
-
Mashup Score: 1Podcasts | VJOncology - 7 day(s) ago
Cancer plays a substantial role in worldwide mortality, accounting for approximately 9.3 million deaths each year. Despite considerable strides made … Prostate cancer stands as the most frequently detected malignant condition among men, ranking as the second primary contributor to cancer-linked … Cancer plays a substantial role in worldwide mortality, accounting for approximately 9.3 million deaths each year. Despite considerable strides made … Prostate cancer stands as the most frequently detected
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
Want to catch up on the latest updates in #oncology? Why not check out our weekly podcasts? 🎤 We've got highlights from the biggest congresses, discussions by leading experts, and deep dives into hot topics! 🗓️New episodes every Friday Listen here:🎧https://t.co/hfihbLPh4O https://t.co/8GXws3PRbY
-
-
Mashup Score: 16
Gaia Griguolo, MD, University of Padova, Padova, Italy, highlights findings from a study which focused on the molecular characterization of brain metastases tissue with next-generation sequencing (NGS) in patients with breast cancer to identify clinically actionable genomic alterations with the ESCAT scale (ESMO Scale for Clinical Actionability of molecular Targets). More than 60% of the mutations were clinically actionable, of which HRD mutations were most prevalent in triple-negative breast cancer. A 20% rate of HRD alterations were seen in the homo-receptor HER2+ breast cancer. This interview took place at 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@GaiaGriguolo of @UniPadova shares insights on NGS of brain metastases in breast cancer, revealing 60% actionable mutations via ESCAT, with HRD most common in #TNBC & HER2+ cases (20%): ➡️https://t.co/DqgIykfWRQ⬅️ @SABCSSanAntonio #SABCS24 #BreastCancer #BCSM #Oncology
-
Our Collaborators at @VJOncology are in San Antonio for #SABCS24 bringing you the highly-anticipated trial data and insightful perspectives from leading experts in #BreastCancer Find their Coverage here: https://t.co/yORESTUyvO Experts include @KalinskyKevin @matteolambe… https://t.co/7qtugUdaHG https://t.co/lruXvOrwc2